Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.
Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory.
复制标题
DOI：
10.1080/10408363.2017.1410520
复制
发表时间：
2017-11
影响因子：
10
通讯作者：
Pallardó FV
中科院分区：
文献类型：
--
作者：
García-Giménez JL;Seco-Cervera M;Tollefsbol TO;Romá-Mateo C;Peiró-Chova L;Lapunzina P;Pallardó FV
表观遗传修饰和调节因子代表了控制相关生理和病理特征的潜在分子元件，从而有助于人类疾病的自然史。这些表观遗传调节剂可用作疾病生物标志物，因为它们显示出几个优点并提供有关基因功能的信息，从而解释患者内表型之间的差异。此外，表观遗传生物标志物可以整合有关环境和生活方式对健康和疾病影响的信息，并监测所应用疗法的效果。用于分析这些表观遗传生物标志物的技术正在不断改进，变得更容易使用。实验室专业人员可以很容易地获得经验和技术变得更加负担得起。大量的表观遗传生物标志物候选物不断被提出，使得现在是在临床实验室中采用表观遗传学并将表观遗传标记转化为可靠生物标志物的时刻。在这篇综述中，我们描述了目前一些有前途的表观遗传生物标志物和技术正在应用于临床实践。此外，我们将讨论一些实验室策略和试剂盒，以加快采用表观遗传生物标志物进入临床常规。随着时间的推移，更好的标记物可能会被识别出来，并可能被纳入未来的多靶点检测中，这可能有助于优化其在临床实验室中的应用。这将提高成本效益，从而鼓励治疗诊断的发展和精确医学的应用。
Epigenetic modifications and regulators represent potential molecular elements which control relevant physiological and pathological features, thereby contributing to the natural history of human disease. These epigenetic modulators can be employed as disease biomarkers, since they show several advantages and provide information about gene function, thus explaining differences among patient endophenotypes. In addition, epigenetic biomarkers can incorporate information regarding the effects of the environment and lifestyle on health and disease, and monitor the effect of applied therapies. Technologies used to analyze these epigenetic biomarkers are constantly improving, becoming much easier to use. Laboratory professionals can easily acquire experience and techniques are becoming more affordable. A high number of epigenetic biomarker candidates are being continuously proposed, making now the moment to adopt epigenetics in the clinical laboratory and convert epigenetic marks into reliable biomarkers. In this review, we describe some current promising epigenetic biomarkers and technologies being applied in clinical practice. Furthermore, we will discuss some laboratory strategies and kits to accelerate the adoption of epigenetic biomarkers into clinical routine. The likelihood is that over time, better markers will be identified and will likely be incorporated into future multi-target assays that might help to optimize its application in a clinical laboratory. This will improve cost-effectiveness, and consequently encourage the development of theragnosis and the application of precision medicine.
登录
查看更多内容
影响因子：
1.6
作者：
Bulla, Alexandre;De Witt, Brian;Lescuyer, Pierre
通讯作者：
Lescuyer, Pierre
影响因子：
4.6
作者：
Caserta S;Kern F;Cohen J;Drage S;Newbury SF;Llewelyn MJ
通讯作者：
Llewelyn MJ
影响因子：
4.1
作者：
Debey-Pascher, Svenja;Hofmann, Andrea;Staratschek-Jox, Andrea
通讯作者：
Staratschek-Jox, Andrea
影响因子：
9.3
作者：
Bossuyt, PM;Reitsma, JB;de Vet, HCW
通讯作者：
de Vet, HCW
骨质疏松症血清 miRNA 的合适参考基因和生物标志物的鉴定
影响因子：
4.6
作者：
Chen J;Li K;Pang Q;Yang C;Zhang H;Wu F;Cao H;Liu H;Wan Y;Xia W;Wang J;Dai Z;Li Y
通讯作者：
Li Y